07.31 2023

Another Product of the Group Passed the Consistency Evaluation, Further Expanded the Advantages of the Domestic Market.

On July 31st, Tianjin Tianyao Pharmaceuticals Co.,Ltd., a subsidiary of the Group, announced that its subsidiary Tianjin Jin Yao Pharmaceutical Co., Ltd. received the Notice of Approval for Drug Supplementary Application approved and issued by National Medical Products Administration for Fluorouracil Injection, which approved the drug to pass the consistency evaluation of generic drug quality and efficacy.


It is reported that fluorouracil injection is an anti-tumor drug, mainly used to treat digestive tract tumors, but also commonly used to treat breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer and skin cancer. From the market point of view, according to the national enlarged hospital data of Menet, fluorouracil injection is mainly sold in hospitals in China, and the domestic sales in 2021 and 2022 are 790 million yuan and 740 million yuan respectively.


Upon passing the evaluation, the preparation products of Tianjin Tianyao Pharmaceuticals Co.,Ltd. will have greater competitive advantage in the domestic market. According to the relevant national policies and regulations, drugs that have passed the consistency evaluation are equivalent to the reference medicine in terms of quality and effect, which shall be given appropriate support in terms of medical insurance payment, and should be given priority in the procurement and selection by medical institutions. Up to now, the company has more than 10 products passed the consistency evaluation one after another;


In recent years, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has actively implemented the whole industrial chain layout of "APIs plus preparations" with steroid hormones and amino acids as the core, steadily promoted drug research and development, and continuously expanded its competitive advantages in domestic and foreign markets. According to the data, there are more than 100 ongoing projects in Tianjin Tianyao Pharmaceuticals Co.,Ltd., mainly focusing on new product research and development, consistency evaluation, FDA registration and other aspects, involving immune system, respiratory system, cardiovascular and cerebrovascular diseases, anti-tumor and other therapeutic fields.